Future Stock Price Projections for Blue Solutions Sociãƒâ©tãƒâ© Anonyme

ALBLU fundamental analysis
Snowflake Score
Valuation	2 /6
Future Growth	0 /6
Past Performance	0 /6
Financial Health	0 /6
Dividends	0 /6

ALBLU Stock Overview

Bluelinea Société Anonyme provides healthcare solutions for elderly and disabled people in France.

Bluelinea Société Anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bluelinea Société Anonyme
Historical stock prices
Current Share Price	€1.30
52 Week High	€5.20
52 Week Low	€1.25
Beta	0.86
1 Month Change	-42.44%
3 Month Change	-48.41%
1 Year Change	-73.46%
3 Year Change	-70.57%
5 Year Change	-71.54%
Change since IPO	-74.10%

Recent News & Updates

Dec 14

Bluelinea Société Anonyme (EPA:ALBLU) Is Carrying A Fair Bit Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

	ALBLU	FR Medical Equipment	FR Market
7D	-31.8%	3.6%	-2.0%
1Y	-73.5%	-3.9%	-12.3%

Return vs Industry : ALBLU underperformed the French Medical Equipment industry which returned -3.9% over the past year.

Return vs Market : ALBLU underperformed the French Market which returned -12.3% over the past year.

Price Volatility

Is ALBLU's price volatile compared to industry and market?
ALBLU volatility
ALBLU Average Weekly Movement	10.2%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	5.1%
10% most volatile stocks in FR Market	9.2%
10% least volatile stocks in FR Market	2.9%

Stable Share Price : ALBLU is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time : ALBLU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2006	77	Laurent Levasseur	https://bluelinea.com

Bluelinea Société Anonyme provides healthcare solutions for elderly and disabled people in France. The company offers SERENEA, a nursing call solution; BluePhone, a mobile phone with mobile remote assistance for seniors; BlueGard, a geolocation bracelet; prevention of night fall products; home automation solution for environmental control, opening automation, intercom/videophone, etc.; and fall and smoke detectors, call watches, and key boxes options and accessories. It also provides BlueHub packs and Handi Joysticks; IP nurse call, fugue control, autonomy bracelets, baby protection products, paging, and EHPADOM counters.

Bluelinea Société Anonyme Fundamentals Summary

How do Bluelinea Société Anonyme's earnings and revenue compare to its market cap?
ALBLU fundamental statistics
Market Cap	€5.54m
Earnings (TTM)	-€3.06m
Revenue (TTM)	€7.50m

Is ALBLU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALBLU income statement (TTM)
Revenue	€7.50m
Cost of Revenue	€4.17m
Gross Profit	€3.33m
Other Expenses	€6.39m
Earnings	-€3.06m

Last Reported Earnings

Jun 30, 2021

Earnings per share (EPS)	-0.71
Gross Margin	44.41%
Net Profit Margin	-40.80%
Debt/Equity Ratio	340.5%

How did ALBLU perform over the long term?

See historical performance and comparison

We've recently updated our valuation analysis.

Valuation

Is ALBLU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALBLU?

Other financial metrics that can be useful for relative valuation.

ALBLU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-3.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALBLU's PS Ratio compare to its peers?

Price to Earnings
Price to Sales
Price to Book

ALBLU PS Ratio vs Peers

The above table shows the PS ratio for ALBLU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1x
ALICR I.CERAM	2.5x	35.7%	€3.9m
ALSPW Spineway	0.6x	n/a	€3.2m
ALIMP Implanet	0.5x	28.1%	€2.9m
ALSAF Safe Orthopaedics	0.5x	41.7%	€2.1m
ALBLU Bluelinea Société Anonyme	0.7x	n/a	€5.5m

Price-To-Sales vs Peers : ALBLU is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (1x).

Price to Earnings Ratio vs Industry

How does ALBLU's PE Ratio compare vs other companies in the FR Medical Equipment Industry?

Price to Sales Ratio vs Fair Ratio

What is ALBLU's PS Ratio compared to its Fair PS Ratio ? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALBLU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio : Insufficient data to calculate ALBLU's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ALBLU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value : Insufficient data to calculate ALBLU's fair value for valuation analysis.

Significantly Below Fair Value : Insufficient data to calculate ALBLU's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio : Insufficient data to calculate ALBLU's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Bluelinea Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-6.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company's ability to generate profit. But as Bluelinea Société Anonyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of ALBLU's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
Bluelinea Société Anonyme competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Bluelinea Société Anonyme performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-6.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings : ALBLU is currently unprofitable.

Growing Profit Margin : ALBLU is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend : Insufficient data to determine if ALBLU's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth : Unable to compare ALBLU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry : ALBLU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).

Return on Equity

High ROE : ALBLU has a negative Return on Equity (-345.07%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Bluelinea Société Anonyme's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities : Insufficient data to determine if ALBLU's short term assets cover its short term liabilities .

Long Term Liabilities : Insufficient data to determine if ALBLU's short term assets cover its long term liabilities .

Debt to Equity History and Analysis

Debt Level : ALBLU's net debt to equity ratio (276.5%) is considered high .

Reducing Debt : ALBLU's debt to equity ratio has increased from 2.9% to 340.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway : Insufficient data to determine if ALBLU has enough cash runway based on its current free cash flow .

Forecast Cash Runway : Insufficient data to determine if ALBLU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Dividend

What is Bluelinea Société Anonyme current dividend yield, its reliability and sustainability?

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend : Unable to evaluate ALBLU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend : Unable to evaluate ALBLU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend : Insufficient data to determine if ALBLU's dividends per share have been stable in the past.

Growing Dividend : Insufficient data to determine if ALBLU's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage : Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage : Unable to calculate sustainability of dividends as ALBLU has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Mr. Laurent Levasseur has been the Chairman of the Executive Board at Bluelinea SA since March 2014 and served as its Chief Executive Officer from January 2006 to March 2014.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying : Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares : Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.

Data	Last Updated (UTC time)
Company Analysis	2022/07/03 00:00
End of Day Share Price	2022/07/01 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31